HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) CME Activity Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Britz-Cunningham, S. H. Articles by Adelstein, S. J. Search for Related Content PubMed PubMed Citation Articles by Britz-Cunningham, S. H. Articles by Adelstein, S. J.

Molecular Targeting with Radionuclides: State of the Science^*

¹ Joint Program in Nuclear Medicine, Harvard Medical School, and Department of Radiology, Brigham and Women’s Hospital, Boston, Massachusetts

Inherent in the application of advances in biomedical science to nuclear medicine is the concept of molecular targeting: the in vivo concentration of labeled tracer by a gene, its transcribed DNA, or its protein product. This mechanism of localization has been and is being exploited for both nuclear imaging and radioisotopic therapy. Agents, such as antisense molecules, aptamers, antibodies, and antibody fragments, can be aimed at molecular targets. Tumor and nerve cell receptors provide such targets. So do certain cellular physiologic activities, including metabolism, hypoxia, proliferation, apoptosis, angiogenesis, response to infection, and multiple drug resistance. In this article we review the principles of molecular targeting based on radioisotopic methods and provide examples from the literature. We discuss applications to imaging and therapy and point out the hurdles that must be overcome in bringing molecular targeting to clinical reality.

Key Words: molecular targets • molecular imaging • radioisotopic therapy

This article has been cited by other articles:

				S. M. OKARVI and I. A. JAMMAZ Design, Synthesis, Radiolabeling and In Vitro and In Vivo Characterization of Tumor-antigen- and Antibody-derived Peptides for the Detection of Breast Cancer Anticancer Res, April 1, 2009; 29(4): 1399 - 1409. [Abstract] [Full Text] [PDF]

				L. T. Littleton, B. B. Fileta, R. Massey, and T. I. Wood Kinevac Stability After Reconstitution with Sodium Chloride Injection USP, 0.9% J. Nucl. Med. Technol., March 1, 2009; 37(1): 57 - 59. [Abstract] [Full Text] [PDF]

				M. Liu, R. F. Wang, C. L. Zhang, P. Yan, M. M. Yu, L. J. Di, H. J. Liu, and F. Q. Guo Noninvasive Imaging of Human Telomerase Reverse Transcriptase (hTERT) Messenger RNA with 99mTc-Radiolabeled Antisense Probes in Malignant Tumors J. Nucl. Med., December 1, 2007; 48(12): 2028 - 2036. [Abstract] [Full Text] [PDF]

				M. Friedman, E. Nordberg, I. Hoiden-Guthenberg, H. Brismar, G.P. Adams, F.Y. Nilsson, J. Carlsson, and S. Stahl Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor Protein Eng. Des. Sel., April 23, 2007; (2007) gzm011v1. [Abstract] [Full Text] [PDF]

				A. Orlova, V. Tolmachev, R. Pehrson, M. Lindborg, T. Tran, M. Sandstrom, F. Y. Nilsson, A. Wennborg, L. Abrahmsen, and J. Feldwisch Synthetic Affibody Molecules: A Novel Class of Affinity Ligands for Molecular Imaging of HER2-Expressing Malignant Tumors Cancer Res., March 1, 2007; 67(5): 2178 - 2186. [Abstract] [Full Text] [PDF]

				G. Mariani, P. A. Erba, and A. Signore Receptor-Mediated Tumor Targeting with Radiolabeled Peptides: There Is More to It than Somatostatin Analogs J. Nucl. Med., December 1, 2006; 47(12): 1904 - 1907. [Full Text] [PDF]

				V. Tolmachev, F. Y. Nilsson, C. Widstrom, K. Andersson, D. Rosik, L. Gedda, A. Wennborg, and A. Orlova 111In-Benzyl-DTPA-ZHER2:342, an Affibody-Based Conjugate for In Vivo Imaging of HER2 Expression in Malignant Tumors J. Nucl. Med., May 1, 2006; 47(5): 846 - 853. [Abstract] [Full Text] [PDF]

				S. A. Wickline, A. M. Neubauer, P. Winter, S. Caruthers, and G. Lanza Applications of Nanotechnology to Atherosclerosis, Thrombosis, and Vascular Biology Arterioscler Thromb Vasc Biol, March 1, 2006; 26(3): 435 - 441. [Abstract] [Full Text] [PDF]

				A. B. Wolbarst and W. R. Hendee Evolving and Experimental Technologies in Medical Imaging Radiology, January 1, 2006; 238(1): 16 - 39. [Abstract] [Full Text] [PDF]

				R. M. Sharkey and D. M. Goldenberg Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies J. Nucl. Med., January 1, 2005; 46(1_suppl): 115S - 127S. [Abstract] [Full Text] [PDF]

				M. Dolovich and R. Labiris Imaging Drug Delivery and Drug Responses in the Lung Proceedings of the ATS, December 1, 2004; 1(4): 329 - 337. [Abstract] [Full Text] [PDF]